A Sample Collection Study to Validate the NEPHROCLEAR™ CCL14 Test
- Conditions
- Acute Kidney Injury
- Registration Number
- NCT04785391
- Lead Sponsor
- Astute Medical, Inc.
- Brief Summary
The objective of this sample collection study is to collect urine samples to validate the NEPHROCLEAR™ CCL14 Test in patients with KDIGO stage 2 or 3 AKI. This study is observational and will have no impact on the medical management of the subject.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Males and females 21 years of age or older;
- Receiving care in an intensive care unit;
- Expected to remain in the ICU for at least 48 hours after enrollment;
- Use of indwelling urinary catheter as standard care at the time of enrollment;
- Subject must have acute kidney injury (KDIGO Stage 2 or Stage 3) at the time of sample collection;
- Urine sample must be collected within 36 hours of meeting KDIGO Stage 2 criteria;
- Written informed consent provided by patient or legally authorized representative (LAR).
Exclusion Criteria
- Prior kidney transplantation;
- Comfort-measures-only status;
- Already receiving dialysis (either acute or chronic) or in imminent need of dialysis at the time of enrollment;
- Known infection with human immunodeficiency virus (HIV) or active hepatitis (acute or chronic);
- Special populations, pregnant women, prisoners or institutionalized individuals.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Persistent Severe Acute Kidney Injury as Determined by Physician Adjudication Within 5 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Role CCL14 chemokine signaling pathophysiology acute kidney injury progression KDIGO stages
Comparative diagnostic accuracy CCL14 NGAL KIM-1 TIMP2 IGFBP7 predicting persistent AKI
Clinical utility urine CCL14 biomarker predicting acute kidney injury severity outcomes validation
Impact CCL14 biomarker guided therapy early intervention acute kidney injury patient management
Astute Medical bioMérieux novel AKI biomarkers development Nephrocheck NEPHROCLEAR clinical impact
Trial Locations
- Locations (1)
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center🇺🇸Pittsburgh, Pennsylvania, United StatesResearch Coordinator ManagerContact